“The Role of Litigation in Defining Drug Risks”

It’s subscription-only, so I haven’t read the whole thing yet, but this JAMA article promises to be interesting.

Avorn frequently testifies on the plaintiffs’ side in pharmaceutical litigation.  I haven’t seen the other author (an MD/JD named Aaron Kesselheim), though a Google search brings up this report of an interesting study he performed, concluding that plaintiffs’ experts in birth injury cases tend to be less qualified than their defense counterparts.  Both authors’ brief bios can be seen here.